Congratulations to our Clinical Research team and all partners in the Wakefield Together Research Partnership, joint winners at the NIHR Yorkshire and Humber Research Awards last night!
The Partnership won the “Contribution to COVID-19 Research” category for their work on the Phase III PROVENT Antibody Study – a trial which recruited the first patient in Wakefield (a world first) and provided an alternative form of protection against COVID before vaccines were officially licensed in December 2020.
In March this year, the antibody combination used in the original PROVENT Antibody study (known as ‘Evusheld’) was licensed for the prevention of COVID-19 in patient populations with a poor immune response. Findings from the study are continuing to form an important part of COVID-19 research.
Impact on COVID-19 Research
The Wakefield Together Partnership was represented on the night by our Spectrum team, who picked up the Award on behalf of the Partnership. Other key partners involved in the project include Mid-Yorkshire Hospitals NHS Trust, NIHR Yorkshire & Humber CRN, Yorkshire Ambulance Service (YAS), Bradford and Craven CCG, Conexus Healthcare and South West Yorkshire Partnership Foundation Trust.
Dr Nat Wright, our Clinical Research Director, says, “Winning this Award is a fantastic achievement for our team and allows us to highlight the real importance of Clinical Research in tackling public health priorities – not just within Yorkshire and Humber but nationally. Findings from the PROVENT Study have shown that just one dose of the ‘Evusheld’ antibody combination protects against COVID-19 for around six months and reduced a patient’s COVID-19 risk by 77% in our sample population. The licensing of Evusheld this year further demonstrates the importance of research projects like ours and we’re proud that this medication will continue to support vulnerable patients who aren’t suitable for the standard COVID vaccine.”
Congratulations to our Clinical Research team!